Genomic Health plans to use IDBS's InforSense platform and E-Workbook to capture and manage biomarker data generated by its breast and colon cancer clinical assays, IDBS said this week.
In addition to capturing gene expression data generated by Genomic Health's OncoType Dx tests, which assess the risk of recurrence for breast or colon cancer, the tools will help the company's scientists gain access to the data they need to run experiments and will capture any intellectual property generated in the process, IDBS said. In addition, the tools are expected to help the company automate and standardize data analysis and biomarker annotation.
Joel Robertson, senior manager of laboratory information management system software at Genomic Health, said that "the amount and heterogeneity" of genomic data generated from the company's cancer assays has "increased significantly," and that the IDBS platform will be a useful tool for the company's clinical data management needs now and in the future.
In July, IDBS announced that the Barts and the London NHR Cardiovascular Biomedical Research Unit had selected the InforSense Suite as its data analysis and visualization tool for research into the effects of genes on cardiovascular disease and to examine the impact of genomic variations on disease treatment (BI 07/02/2010).
Genomic Health's adoption of the platform comes amid a bioinformatics scale-up at the company related to its adoption of next-generation sequencing for biomarker discovery (BI9/27/2010).